| HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance S Pernas, SM Tolaney Therapeutic advances in medical oncology 11, 1758835919833519, 2019 | 331 | 2019 |
| HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer … A Llombart-Cussac, J Cortés, L Paré, P Galván, B Bermejo, N Martínez, ... The lancet oncology 18 (4), 545-554, 2017 | 326 | 2017 |
| CDK4/6 inhibition in breast cancer: current practice and future directions S Pernas, SM Tolaney, EP Winer, S Goel Therapeutic advances in medical oncology 10, 1758835918786451, 2018 | 297 | 2018 |
| Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2–positive breast cancer SM Tolaney, H Guo, S Pernas, WT Barry, DA Dillon, L Ritterhouse, ... Journal of Clinical Oncology 37 (22), 1868, 2019 | 279 | 2019 |
| Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer R Barroso-Sousa, TE Keenan, S Pernas, P Exman, E Jain, ... Clinical cancer research 26 (11), 2565-2572, 2020 | 143 | 2020 |
| Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial S Pernas, M Martin, PA Kaufman, M Gil-Martin, PG Pardo, ... The Lancet Oncology 19 (6), 812-824, 2018 | 124 | 2018 |
| HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis F Schettini, T Pascual, B Conte, N Chic, F Brasó-Maristany, P Galván, ... Cancer treatment reviews 84, 101965, 2020 | 119 | 2020 |
| A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual … P Nuciforo, T Pascual, J Cortés, A Llombart-Cussac, R Fasani, L Paré, ... Annals of Oncology 29 (1), 170-177, 2018 | 99 | 2018 |
| Avoiding axillary treatment in sentinel lymph node micrometastases of breast cancer: a prospective analysis of axillary or distant recurrence S Pernas, M Gil, A Benítez, MT Bajen, F Climent, MJ Pla, E Benito, ... Annals of surgical oncology 17, 772-777, 2010 | 96 | 2010 |
| Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer M Hergueta-Redondo, D Sarrio, Á Molina-Crespo, R Vicario, ... Oncotarget 7 (35), 56295, 2016 | 89 | 2016 |
| Palbociclib and trastuzumab in HER2-positive advanced breast cancer: results from the phase II SOLTI-1303 PATRICIA trial E Ciruelos, P Villagrasa, T Pascual, M Oliveira, S Pernas, L Paré, ... Clinical Cancer Research 26 (22), 5820-5829, 2020 | 87 | 2020 |
| Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade F Brasó-Maristany, G Griguolo, T Pascual, L Paré, P Nuciforo, ... Nature communications 11 (1), 385, 2020 | 82 | 2020 |
| Resistance to taxanes in triple-negative breast cancer associates with the dynamics of a CD49f+ tumor-initiating population J Gómez-Miragaya, M Palafox, L Paré, G Yoldi, I Ferrer, S Vila, P Galván, ... Stem cell reports 8 (5), 1392-1407, 2017 | 78 | 2017 |
| A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation A Prat, V Guarneri, L Paré, G Griguolo, T Pascual, MV Dieci, N Chic, ... The Lancet Oncology 21 (11), 1455-1464, 2020 | 63 | 2020 |
| Optimal treatment of early stage HER2‐positive breast cancer S Pernas, R Barroso‐Sousa, SM Tolaney Cancer 124 (23), 4455-4466, 2018 | 63 | 2018 |
| Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain JI Mayordomo, A López, N Viñolas, J Castellanos, S Pernas, ... Current medical research and opinion 25 (10), 2533-2542, 2009 | 60 | 2009 |
| A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study B Martin-Castillo, S Pernas, J Dorca, I Álvarez, S Martínez, ... Oncotarget 9 (86), 35687, 2018 | 59 | 2018 |
| SEOM clinical guidelines in early stage breast cancer (2018) F aYaLa dE La PEña, R Andrés, JA Garcia-Saenz, L Manso, M Margelí, ... Clinical and Translational Oncology 21, 18-30, 2019 | 54 | 2019 |
| Metformin and breast cancer: where are we now? M Cejuela, B Martin-Castillo, JA Menendez, S Pernas International journal of molecular sciences 23 (5), 2705, 2022 | 44 | 2022 |
| 18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial M Quintela-Fandino, A Lluch, L Manso, I Calvo, J Cortes, ... Clinical Cancer Research 23 (6), 1432-1441, 2017 | 44 | 2017 |
